Pfizer Czech Republic's net debt stood at CZK 329 mil and accounted for 24.2% of equity at the end of 2017. The ratio is up 24.7 pp compared to the previous year.
Historically, the firm’s net debt to equity reached a high of 199% in 2006 and a low of -150% in 2004 between 2002 and 2017. The average for the last five years was 1.03%.
Net debt to EBITDA was calculated at 2.10x at the end of the year. That is up from -1.32x seen in 2012. The ratio reached a high of 5.38x in 2005 and a low of -1.65x in 2014.
The company’s cost of funding amounted to 3.65% in 2017, up which is above the 5-year of 3.65%. Funding costs have “eaten” some 4.67% of the operating profit generated in 2019.
You can see all the company’s data at Pfizer Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
